BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
NEMLUVIO (nemolizumab-ilto) by Galderma is interleukin-31 receptor alpha antagonists [moa]. Approved for prurigo nodularis, atopic dermatitis. First approved in 2024.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEMLUVIO (nemolizumab-ilto) is a monoclonal antibody that blocks interleukin-31 receptor alpha, a key driver of itch signaling in the skin. It is approved for prurigo nodolaris and atopic dermatitis, two severe inflammatory skin conditions characterized by intense pruritus. This represents a novel mechanism targeting itch directly rather than general immune suppression.
Growth
Recently approved biologic in growth phase with limited Medicare data to date; Galderma brand team is in early commercialization with potential to expand as real-world utilization data matures.
Mechanism of Action
Interleukin-31 Receptor alpha Antagonists
Pharmacologic Class:
Interleukin-31 Receptor alpha Antagonist
Indications (2)
Worked on NEMLUVIO at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.